Evoke Pharma Company Profile (NASDAQ:EVOK)

About Evoke Pharma

Evoke Pharma logoEvoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EVOK
  • CUSIP:
Key Metrics:
  • Previous Close: $3.10
  • 50 Day Moving Average: $2.67
  • 200 Day Moving Average: $2.10
  • 52-Week Range: $12,350,000.00 - $1.35
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.43
  • P/E Growth: -0.06
  • Market Cap: $38.29M
  • Outstanding Shares: 12,350,000
  • Beta: 1.06
Profitability:
  • Return on Equity: -612.23%
  • Return on Assets: -142.10%
Debt:
  • Current Ratio: 10.70%
  • Quick Ratio: 10.70%
Additional Links:
Companies Related to Evoke Pharma:

Analyst Ratings

Consensus Ratings for Evoke Pharma (NASDAQ:EVOK) (?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $11.13 (258.87% upside)

Analysts' Ratings History for Evoke Pharma (NASDAQ:EVOK)
Show:
DateFirmActionRatingPrice TargetDetails
1/31/2017FBR & CoReiterated RatingOutperform -> Positive$9.00View Rating Details
1/30/2017LaidlawUpgradeNeutral -> Buy$8.00View Rating Details
1/5/2017Rodman & RenshawUpgradeNeutral -> Buy$2.50 -> $6.00View Rating Details
1/5/2017HC WainwrightUpgradeNeutral -> BuyView Rating Details
8/16/2016Noble FinancialReiterated RatingHoldView Rating Details
7/18/2016Northland SecuritiesDowngradeOutperform -> Market PerformView Rating Details
7/18/2016Feltl & Co.DowngradeStrong-Buy -> SellView Rating Details
7/18/2016Brean CapitalDowngradeBuy -> HoldView Rating Details
3/14/2016Ascendiant Capital MarketsBoost Price TargetBuy$11.00 -> $12.00View Rating Details
5/15/2015Cantor FitzgeraldReiterated RatingBuy$20.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Evoke Pharma (NASDAQ:EVOK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/9/2016Q316($0.26)($0.29)ViewListenView Earnings Details
8/15/2016Q216($0.43)($0.41)ViewListenView Earnings Details
5/11/2016Q116($0.41)($0.45)ViewListenView Earnings Details
3/10/2016Q415($0.45)($0.37)ViewListenView Earnings Details
11/12/2015Q315($0.54)($0.42)ViewListenView Earnings Details
8/13/2015Q215($0.60)($0.52)ViewListenView Earnings Details
5/14/2015Q115($0.55)($0.58)ViewListenView Earnings Details
3/4/2015Q414($0.68)($0.48)ViewN/AView Earnings Details
11/13/2014($0.78)($0.63)ViewN/AView Earnings Details
8/13/2014($0.73)($0.59)ViewN/AView Earnings Details
5/13/2014Q114($0.36)($0.49)ViewN/AView Earnings Details
3/25/2014Q413($0.16)($0.27)ViewN/AView Earnings Details
11/13/2013Q3 13($0.10)($0.41)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Evoke Pharma (NASDAQ:EVOK)
Current Year EPS Consensus Estimate: $-1.25 EPS
Next Year EPS Consensus Estimate: $-0.70 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.48)($0.37)($0.43)
Q2 20162($0.47)($0.47)($0.47)
Q3 20162($0.42)($0.29)($0.36)
Q4 20162($0.22)($0.22)($0.22)
Q1 20171($0.17)($0.17)($0.17)
Q2 20171($0.18)($0.18)($0.18)
Q3 20171($0.18)($0.18)($0.18)
Q4 20171($0.17)($0.17)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Evoke Pharma (NASDAQ:EVOK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Evoke Pharma (NASDAQ:EVOK)
Insider Ownership Percentage: 30.50%
Institutional Ownership Percentage: 5.60%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2017Kenneth J WidderDirectorBuy450,000$2.90$1,305,000.00View SEC Filing  
5/26/2016Parters Vii L P DomainMajor ShareholderSell344,120$4.70$1,617,364.00View SEC Filing  
4/27/2016Parters Vii L P DomainMajor ShareholderSell5,095$5.07$25,831.65View SEC Filing  
4/25/2016Parters Vii L P DomainMajor ShareholderSell1,492$5.20$7,758.40View SEC Filing  
4/20/2016Parters Vii L P DomainMajor ShareholderSell41,478$5.35$221,907.30View SEC Filing  
4/11/2016Parters Vii L P DomainMajor ShareholderSell4,348$5.22$22,696.56View SEC Filing  
4/8/2016Parters Vii L P DomainMajor ShareholderSell51,004$5.28$269,301.12View SEC Filing  
8/18/2015Parters Vii L P DomainMajor ShareholderSell11,836$7.02$83,088.72View SEC Filing  
4/16/2015Parters Vii L P DomainMajor ShareholderSell50,163$7.29$365,688.27View SEC Filing  
9/23/2014Todd C BradyDirectorBuy4,000$5.70$22,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Evoke Pharma (NASDAQ:EVOK)
DateHeadline
News IconAre Analysts Optimistic About Where Evoke Pharma, Inc. (NASDAQ:EVOK) is Heading? - Winfield Review (NASDAQ:EVOK)
winfieldreview.com - February 26 at 9:07 AM
News IconNews Impact Score Of Evoke Pharma, Inc. (NASDAQ:EVOK) At 50 - Stock Observer (NASDAQ:EVOK)
www.thestockobserver.com - February 26 at 9:07 AM
marketexclusive.com logoInsider Trading Activity Evoke Pharma, Inc. (NASDAQ:EVOK) – Director Bought 450000 shares of Stock - Market Exclusive (NASDAQ:EVOK)
marketexclusive.com - February 26 at 9:07 AM
streetinsider.com logoForm 3 Evoke Pharma Inc For: Feb 22 Filed by: LATTERELL PATRICK F (NASDAQ:EVOK)
www.streetinsider.com - February 24 at 10:59 PM
News IconShares in Review: Evoke Pharma Inc (EVOK) - Rives Journal (NASDAQ:EVOK)
rivesjournal.com - February 22 at 5:23 PM
News IconEvoke Pharma, Inc. NASDAQ:EVOK Sees Unusual Volatility in Session - Aiken Advocate (NASDAQ:EVOK)
aikenadvocate.com - February 22 at 5:23 PM
News IconStock Price of Evoke Pharma, Inc. (EVOK) Increases 25.46 ... - Highland Mirror (NASDAQ:EVOK)
www.highlandmirror.com - February 22 at 5:23 PM
News IconWatching the Charts on Evoke Pharma Inc. (EVOK) - Benton Bulletin (NASDAQ:EVOK)
bentonbulletin.com - February 18 at 5:56 AM
News IconPrice Target Roundup on Evoke Pharma, Inc. (NASDAQ:EVOK) Phoenix New Media Limited (NYSE:FENG) - Rives Journal (NASDAQ:EVOK)
rivesjournal.com - February 17 at 3:19 PM
News IconThe Technicals For Evoke Pharma, Inc. (EVOK) Have Been Dissected (Brutally) - NY Stock News (NASDAQ:EVOK)
nystocknews.com - February 17 at 3:19 PM
News IconTechnical Focus on Shares of Evoke Pharma Inc. (EVOK) - BVN (NASDAQ:EVOK)
bvnewsjournal.com - February 17 at 9:18 AM
News IconMost Volatile Market Movers: Zosano Pharma Corporation (NASDAQ:ZSAN), Evoke Pharma, Inc. (NASDAQ:EVOK) - Street Wise Report (blog) (NASDAQ:EVOK)
streetwisereport.com - February 17 at 9:18 AM
streetinsider.com logoEvoke Pharma (EVOK) Plans Offering of Common Stock - StreetInsider.com (NASDAQ:EVOK)
www.streetinsider.com - February 17 at 9:18 AM
reuters.com logoBRIEF-Evoke Pharma announces proposed public offering of common stock (NASDAQ:EVOK)
www.reuters.com - February 16 at 5:01 PM
rttnews.com logoEvoke Pharma Inc. (EVOK) Has Jumped To A 6-Month High On FDA Exemption (NASDAQ:EVOK)
www.rttnews.com - February 16 at 5:01 PM
4-traders.com logoEvoke Pharma : FDA Exempts Evoke from Requirement for Human Factor Validation Study (NASDAQ:EVOK)
www.4-traders.com - February 16 at 5:01 PM
News IconKey FDA Exemption Clears the Way for Shares of Evoke Pharma Inc (NASDAQ:EVOK) (NASDAQ:EVOK)
streetregister.com - February 16 at 5:01 PM
schaeffersresearch.com logoShopify, Sirius XM, Evoke Pharma Stocks Moving Today (NASDAQ:EVOK)
www.schaeffersresearch.com - February 16 at 5:01 PM
finance.yahoo.com logoFDA Exempts Evoke from Requirement for Human Factor Validation Study (NASDAQ:EVOK)
finance.yahoo.com - February 16 at 5:01 PM
biz.yahoo.com logoEVOKE PHARMA INC Files SEC form 8-K, Other Events (NASDAQ:EVOK)
biz.yahoo.com - February 16 at 5:01 PM
marketwatch.com logoEvoke Pharma's stock soars after FDA exempts Gimoti from HF Validation (NASDAQ:EVOK)
www.marketwatch.com - February 16 at 5:01 PM
finance.yahoo.com logoWhy Evoke Pharma Shares Are Exploding (NASDAQ:EVOK)
finance.yahoo.com - February 16 at 5:01 PM
finance.yahoo.com logoEvoke Pharma Announces Proposed Public Offering of Common Stock (NASDAQ:EVOK)
finance.yahoo.com - February 16 at 5:01 PM
finance.yahoo.com logoEvoke Pharma Announces Pricing of Public Offering of Common Stock (NASDAQ:EVOK)
finance.yahoo.com - February 16 at 5:01 PM
finance.yahoo.com logo8:47 am Evoke Pharma prices 2,413,793 share offering at $2.90/share (NASDAQ:EVOK)
finance.yahoo.com - February 16 at 5:01 PM
finance.yahoo.com logoBiotech Industry Poised for a Breakout in 2017? Today's Reports on Evoke Pharma and Novavax (NASDAQ:EVOK)
finance.yahoo.com - February 16 at 5:01 PM
biz.yahoo.com logoEVOKE PHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:EVOK)
biz.yahoo.com - February 16 at 5:01 PM
News IconTechnical Trading: Focus on Shares of Evoke Pharma Inc. (EVOK) - Rives Journal (NASDAQ:EVOK)
rivesjournal.com - February 13 at 10:55 PM
News IconNews Impact Score Of Evoke Pharma, Inc. (NASDAQ:EVOK) At 66 - Stock Observer (NASDAQ:EVOK)
www.thestockobserver.com - February 12 at 10:02 PM
News IconTrading Scope: Watching Shares of Evoke Pharma Inc. (EVOK) - Davidson Register (NASDAQ:EVOK)
davidsonregister.com - February 11 at 3:43 AM
News IconEarnings Take Center Stage; Analysts Weighing in on Evoke Pharma, Inc. (NASDAQ:EVOK) - Aiken Advocate (NASDAQ:EVOK)
aikenadvocate.com - February 10 at 3:44 AM
News IconWatching Technical Levels on Shares of Evoke Pharma Inc. (EVOK) - Rives Journal (NASDAQ:EVOK)
rivesjournal.com - February 8 at 4:21 AM
News IconMarket Focus- Increased Volatility Recorded on Shares of Evoke Pharma, Inc. (NASDAQ:EVOK) - Davidson Register (NASDAQ:EVOK)
davidsonregister.com - February 7 at 3:10 AM
prnewswire.com logoHow These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke Pharma, SCYNEXIS, and Eagle Pharma (NASDAQ:EVOK)
www.prnewswire.com - February 3 at 5:30 PM
News IconStock ready to Pivot? Focus on Shares of Evoke Pharma, Inc. (NASDAQ:EVOK) - Prospect Journal (NASDAQ:EVOK)
prospectjournal.com - January 31 at 10:46 PM
News IconCalling all Bargain Hunters: Stock Update on Evoke Pharma, Inc. (NASDAQ:EVOK) - Prospect Journal (NASDAQ:EVOK)
prospectjournal.com - January 31 at 10:46 PM
News IconStock Vacillating as Volatility Hits a High Point For Evoke Pharma, Inc. (NASDAQ:EVOK) - Wall Street Beacon (NASDAQ:EVOK)
wsbeacon.com - January 31 at 10:46 PM
News IconCalibrating the Trade: Watching Technicals on Shares of Evoke Pharma Inc. (EVOK) - Sherwood Daily (NASDAQ:EVOK)
sherwooddaily.com - January 30 at 9:30 PM
News IconEvoke Pharma Inc (EVOK) Forms Bearish Multiple Bottom Chart Pattern; Strong Momentum for Sellers - The Randolph Guide (NASDAQ:EVOK)
randolphguide.com - January 30 at 9:30 PM
News IconHigh Volatility Moving the Needle For Shares of Evoke Pharma, Inc. (NASDAQ:EVOK) - Wall Street Beacon (NASDAQ:EVOK)
wsbeacon.com - January 30 at 9:30 PM
News IconEvoke Pharma Inc (EVOK) is Upgraded by Laidlaw to ” Buy ... - Highland Mirror (NASDAQ:EVOK)
www.highlandmirror.com - January 30 at 9:30 PM
seekingalpha.com logoLaidlaw likes Evoke, sees 189% upside; shares ahead 12% - Seeking Alpha (NASDAQ:EVOK)
seekingalpha.com - January 30 at 9:30 PM
finance.yahoo.com logoEvoke Pharma upgraded by Laidlaw (NASDAQ:EVOK)
finance.yahoo.com - January 30 at 4:29 PM
streetinsider.com logoForm 4 Evoke Pharma Inc For: Jan 25 Filed by: Gonyer David A - StreetInsider.com (NASDAQ:EVOK)
www.streetinsider.com - January 29 at 3:17 AM
News IconStock Momentum in Focus on Shares of Evoke Pharma Inc. (EVOK) - Sherwood Daily (NASDAQ:EVOK)
sherwooddaily.com - January 27 at 6:47 PM
News IconStock Tracker: Earnings & Estimates for Evoke Pharma, Inc. (NASDAQ:EVOK) - Aiken Advocate (NASDAQ:EVOK)
aikenadvocate.com - January 27 at 6:47 PM
News IconEarnings in Full Force, Analysts Take Aim at Evoke Pharma, Inc. (NASDAQ:EVOK) - Wall Street Beacon (NASDAQ:EVOK)
wsbeacon.com - January 27 at 6:47 PM
News IconHigh Volatility Creating Buzz Mid-Session For Evoke Pharma, Inc. (NASDAQ:EVOK) - Wall Street Beacon (NASDAQ:EVOK)
wsbeacon.com - January 27 at 6:47 PM
News IconTrading Spotlight: Zooming in on Shares of Evoke Pharma Inc. (EVOK) - Sherwood Daily (NASDAQ:EVOK)
sherwooddaily.com - January 26 at 6:30 PM
News IconMonitoring Relative Strength Index Values for Evoke Pharma Inc. (EVOK) - Sherwood Daily (NASDAQ:EVOK)
sherwooddaily.com - January 26 at 4:31 AM

Social

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

Where is Evoke Pharma's stock going? Where will Evoke Pharma's stock price be in 2017?

9 analysts have issued 12 month price objectives for Evoke Pharma's shares. Their forecasts range from $3.00 to $22.00. On average, they anticipate Evoke Pharma's share price to reach $11.13 in the next twelve months.

When will Evoke Pharma announce their earnings?

Evoke Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

What are analysts saying about Evoke Pharma stock?

Here are some recent quotes from research analysts about Evoke Pharma stock:

  • According to Zacks Investment Research, "Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. " (11/14/2016)

  • Rodman & Renshaw analysts commented, "We are expecting Evoke to report top-line data within the next couple of weeks from the Phase 3 trial of its lead candidate, EVK-001 (intranasal metoclopramide), in women with diabetic gastroparesis. We anticipate that these results, if positive, should enable Evoke to file directly for approval of EVK-001 in the U.S. via the 505(b)(2) pathway. In anticipation of positive results from this trial, we reiterate our Buy rating and 12-month price target of $27.00 on EVOK shares. Phase 3 trial robustly powered, in our view. The METO-IN-003 trial has enrolled roughly 200 adult women with diabetic gastroparesis, and was formally completed at the beginning of June. The primary endpoint is change from baseline in symptom score at week 4 utilizing a proprietary Patient Reported Outcome (PRO) instrument. The study size reflects 90% power (alpha=0.05 two-sided, SD=0.65) to detect a mean difference of 0.3 between the treatment and placebo groups. We note that the Phase 2b EVK-001 trial reached statistical significance in women (p=0.0247) and that the drug group showed a >50% improvement in mean gastroparesis total symptom score change from baseline." (7/11/2016)

  • Brean Capital analysts commented, "Evoke beat expectations on Q4 results. However, we look to the completion of enrollment in 2Q16 and Phase III read-out in 3Q16 (as early as July 2016) as the next key catalysts. NDA is expected to file after the read-out in 3Q16. With a strong risk/reward profile, we believe that it is likely that the clinical trial of EVK-001 achieves a positive read-out." (3/11/2016)

How do I buy Evoke Pharma stock?

Shares of Evoke Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Evoke Pharma stock cost?

One share of Evoke Pharma stock can currently be purchased for approximately $3.10.

Evoke Pharma (NASDAQ:EVOK) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Evoke Pharma (NASDAQ:EVOK)

Earnings History Chart

Earnings by Quarter for Evoke Pharma (NASDAQ:EVOK)

Dividend History Chart

Dividend Payments by Quarter for Evoke Pharma (NASDAQ:EVOK)

Last Updated on 2/27/2017 by MarketBeat.com Staff